Mechelen Belgium; 12 December 2016 Galapagos NV Euronext & NASDAQ GLPG reports publication of the Phase 2 study with filgotinib in Crohn's disease in The Lancet. "Filgotinib a selective JAK1 inhibitor induces cl...
↧